Herpes zoster cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Varun Kumar (talk | contribs) (Created page with "{{Herpes zoster}} {{CMG}}; L. Katie Morrison, MD; '''Associate Editor(s)-In-Chief:''' {{CZ}} {{EJ}} ==References== {{Reflist|2}} Category:Infectious skin diseases [[Cate...") |
m (Bot: Removing from Primary care) |
||
| (7 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Herpes zoster}} | {{Herpes zoster}} | ||
{{CMG | {{CMG}} | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
==Overview== | |||
A live [[vaccine]] for VZV exists, marketed as [[Zostavax]].<ref name="MMWR_57(05)">{{cite journal | |||
| author = Harpaz R, Ortega-Sanchez IR, Seward JF | |||
| title = Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP) | |||
| journal = MMWR Recomm Rep | |||
| volume = 57 | |||
| issue = RR–5 | |||
| pages = 1–30; quiz CE2–4 | |||
| date = June 6, 2008 | |||
| pmid = 18528318 | |||
| doi = | |||
| url = http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm | |||
| accessdate = 2010-01-04 | |||
}}</ref> A systematic review by the [[Cochrane Library]] concluded that Zostavax can reduce the incidence of herpes zoster by almost 50%.<ref>{{cite journal |author=Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG |title=Vaccines for preventing herpes zoster in older adults |journal=Cochrane Database Syst Rev |volume=10 |issue= |pages=CD008858 |year=2012 |pmid=23076951 |doi=10.1002/14651858.CD008858.pub2 |editor1-last=Gagliardi |editor1-first=Anna MZ}}</ref> A 2007 study found that the zoster vaccine is likely to be cost-effective in the U.S., projecting an annual savings of $82 to $103 million in healthcare costs with cost-effectiveness ratios ranging from $16,229 to $27,609 per [[quality-adjusted life year]] gained.<ref>{{cite journal |journal=Vaccine |year=2007 |volume=25 |issue=49 |pages=8326–37 |title= Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults |author= Pellissier JM, Brisson M, Levin MJ |doi=10.1016/j.vaccine.2007.09.066 |pmid=17980938}}</ref> In October 2007 the vaccine was officially recommended in the U.S. for healthy adults aged 60 and over.<ref name="MMWR_57(05)"/><ref name=pmid17947396>{{cite journal |journal= Ann Intern Med |date=20 November 2007|volume=147 |issue=10 |pages=725–9 |title= Recommended adult immunization schedule: United States, October 2007 – September 2008 |author= Advisory Committee on Immunization Practices |pmid=17947396 |url=http://www.annals.org/cgi/content/full/147/10/725 |doi= 10.7326/0003-4819-147-10-200711200-00187 }}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WS}} | |||
{{WH}} | |||
[[Category:Infectious skin diseases]] | [[Category:Infectious skin diseases]] | ||
[[Category:Viral diseases]] | [[Category:Viral diseases]] | ||
[[Category:Herpesviruses]] | [[Category:Herpesviruses]] | ||
[[Category: | [[Category:Needs content]] | ||
Latest revision as of 22:09, 29 July 2020
|
Herpes zoster Microchapters |
|
Diagnosis |
|---|
|
History and Symptoms |
|
Treatment |
|
Case Studies |
|
Herpes zoster cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Herpes zoster cost-effectiveness of therapy |
|
Risk calculators and risk factors for Herpes zoster cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
A live vaccine for VZV exists, marketed as Zostavax.[1] A systematic review by the Cochrane Library concluded that Zostavax can reduce the incidence of herpes zoster by almost 50%.[2] A 2007 study found that the zoster vaccine is likely to be cost-effective in the U.S., projecting an annual savings of $82 to $103 million in healthcare costs with cost-effectiveness ratios ranging from $16,229 to $27,609 per quality-adjusted life year gained.[3] In October 2007 the vaccine was officially recommended in the U.S. for healthy adults aged 60 and over.[1][4]
References
- ↑ 1.0 1.1 Harpaz R, Ortega-Sanchez IR, Seward JF (June 6, 2008). "Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep. 57 (RR–5): 1–30, quiz CE2–4. PMID 18528318. Retrieved 2010-01-04.
- ↑ Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG (2012). Gagliardi, Anna MZ, ed. "Vaccines for preventing herpes zoster in older adults". Cochrane Database Syst Rev. 10: CD008858. doi:10.1002/14651858.CD008858.pub2. PMID 23076951.
- ↑ Pellissier JM, Brisson M, Levin MJ (2007). "Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults". Vaccine. 25 (49): 8326–37. doi:10.1016/j.vaccine.2007.09.066. PMID 17980938.
- ↑ Advisory Committee on Immunization Practices (20 November 2007). "Recommended adult immunization schedule: United States, October 2007 – September 2008". Ann Intern Med. 147 (10): 725–9. doi:10.7326/0003-4819-147-10-200711200-00187. PMID 17947396.